SYNTHESIS OF TARGETED CONDENSED THIOIMIDAZOLES

Martyna Paulauskaitė[1], Gintarė Sapežinskaitė[2], Indrė Misiūnaitė[1], Ieva Žutautė[1]

[1]Faculty of Chemistry and Geosciences, Vilnius University, Lithuania
[2]Faculty of Medicine, Vilnius University, Lithuania
martyna.paulauskaite@chgf.stud.vu.lt

There is an increasing interest in the research of protein aggregation and the formation of amyloid structures in various scientific fields. This heightened interest is driven by the connection between amyloid deposition and numerous serious medical conditions, including Alzheimer and Parkinson diseases, type II diabetes, and many systemic amyloidoses. In todayś world, these disorders pose a major threat to human health and well-being, so more detailed research is needed [1]. A growing number of studies have described a variety of inhibitors targeting self-assembled amyloidogenic proteins, and some of these are presently undergoing clinical trials. These inhibitors can be categorized into small molecules, short peptides, and antibodies [2].

Recent preliminary studies of imidazothiazines synthesized in our laboratory have shown potential inhibition of amyloid aggregation. Consequently, targeted synthesis of imidazothiazoles, imidazothiazines and imidazothiazepines from aryl propargylic bromides and the corresponding imidazoles for inhibition of amyloid aggregation is in progress. A more detailed analysis of the synthesis will be discussed during the presentation. Studies are being carried out on insulin, a commonly used protein to study the formation of amyloid fibrils [3], and on alpha-synuclein, a Parkinsonś disease-related protein [4].



Fig. 1. Retrosynthetic scheme for the targeted synthesis of imidazothiazoles, imidazothiazines and imidazothiazepines

[1] F. Chiti, C. M. Bobson, Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu. Rev. Biochem. 2017, 86, 27-68.
[2] B. Cheng, et. al., Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases. Biochim. Biophys. Acta. 2013, 1830 (10), 4860-4871.
[3] A. Sakalauskas, et. al., Concentration-dependent polymorphism of insulin amyloid fibrils, PeerJ. 2019, 7 1-13.
[4] M. Ziaunys, et. al., Polymorphism of Alpha-Synuclein Amyloid Fibrils Depends on Ionic Strength and Protein Concentration. Int. J. Mol. Sci. 2021, 22, 12382.